MercachemSyncom completed the acquisition Alcami Weert.

MercachemSyncom, a mid-sized European drug-discovery contract research organization, completed the acquisition of European cGMP CMC drug substance development site, based in Weert, from Alcami, a US-based contract development, testing, and manufacturing organization. Financial terms were not disclosed. “Since the merger of Mercachem and Syncom in 2017, our activities in early drug substance development have grown significantly; however, it is a real challenge to find experienced development chemists – both analytical and synthetic. With the addition of the Alcami Weert team, we have the perfect technical and cultural match. With modern, flexible plant capacity, we look forward to supporting many more clinical development programs for our customers,” Frank Leemhuis, MercachemSyncom Managing Director.